This document lists observations made by the FDA representative(s) during the inspection of your facility. They are inspectional observations, and do not represent a final Agency determination regarding your compliance. If you have an objection regarding an observation, or have implemented, or plan to implement, corrective action in response to an observation, you may discuss the objection or action with the FDA representative(s) during the inspection or submit this information to FDA at the address above. If you have any questions, please contact FDA at the phone number and address above.

DURING AN INSPECTION OF YOUR FIRM I OBSERVED:

OBSERVATION 1

You used a non-pharmaceutical grade component in the formulation of a drug product.

Specifically, your firm used \( b \) water in the production of a released and distributed drug product. \( b \) water was used in the production of Rx \( b \), Amlodipine 1mg/mL, for a pediatric population.

*DATES OF INSPECTION
8/21/2018(Tue), 8/23/2018(Thu), 8/28/2018(Tue), 9/05/2018(Wed)